Deep learning enables diagnosis of atrial cardiomyopathy from routine 12-lead electrocardiogram

Abstract

Background and Aims Atrial cardiomyopathy (AtCM) contributes to the development of atrial fibrillation (AF), heart failure (HF) and stroke. Imaging-derived measures of left atrial (LA) structure and function are used to diagnose AtCM. Considering the tight coupling of heart structure and rhythm generation, this information might also be derived from 12-lead electrocardiogram (ECG), which is low-cost and readily available.

Methods We finetuned a deep learning (DL) ECG foundational model to predict LA imaging indices based on 26’134 ECGs from the UK Biobank cohort. We then investigated if the ECG-predicted imaging features improved risk stratification of AF beyond the CHARGE-AF Score on a test set from the UK Biobank. We repeated this analysis for diagnosis of HF. We then externally validated our model and applied it to a cohort of stroke patients.

Results Our DL model successfully predicted LA imaging indices from 12 lead ECG. In the UK Biobank test set, the ECG-predicted LA imaging features significantly improved risk stratification for AF beyond the CHARGE-AF score. ECG-predicted imaging markers showed superior test performance compared to established ECG markers of AtCM and an alternative DL approach This also held on external validation sets. Importantly, the predicted imaging features improved risk stratification for HF in the UK Biobank, even when excluding patients with AF, suggesting that our model captures AtCM beyond AF.

Discussion We established a novel DL approach for the diagnosis of AtCM from 12 lead ECG. Due to the wide availability of ECG, our approach has the potential to improve screening and diagnosis of AtCM.

Key Question Can left atrial imaging markers of atrial cardiomyopathy predicted from 12 lead electrocardiogram (ECG) using a deep learning (DL) model improve risk stratification for atrial fibrillation (AF) and heart failure (HF)?

Key Finding Our DL model successfully predicted left atrial imaging features from 12 lead ECG. The predicted left atrial imaging markers improved risk stratification for AF and HF outperforming a deep learning model trained to identify patients with AF directly.

Take-home message DL allows improved diagnosis of atrial cardiomyopathy from ECG.

• Download figure
• Open in new tab

Structured graphical abstract showing the model training and evaluation procedure.

We first trained a deep learning model to predict left atrial imaging markers of atrial cardiomyopathy. We then added the predicted imaging features to clinical risk scores, creating multivariate regression models for risk stratification of different clinical outcomes. Finally, we externally validate the deep learning model and derived multivariate regression models on a diverse set of clinical cohorts.

Competing Interest Statement

JS has received consultant and / or speaker fees from Abbott, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Daiichi Sankyo, Medscape, Medtronic, Menarini, Pfizer, Saja, and WebMD. He reports ownership of Swiss EP and CorXL. AB has received consulting/presenter fees from Abbott, Angiodynamics, Bayer Health Care, Biosense Webster, Biotronik, BMS/Pfizer, Boston Scientific, Cook Medical, Daiichi Sankyo, Medtronic, Philips, and Zoll. SW received research funds by the Swiss National Science Foundation, the UZH Clinical research priority program (CRPP) stroke, the Zurich Neuroscience Center (ZNZ), the Baugarten foundation, the Hartmann Müxller Foundation, the Koetser Foundation, the Philas Foundation, the Swiss Heart Foundation; and speaker honoraria from Amgen, Springer, Advisis AG, Teva Pharma, Boehringer Ingelheim, Lundbeck, Astra Zeneca, FoMF, and a consultancy fee from Bayer and Novartis via institution for research. The remaining authors report no conflicts of interest.

Funding Statement

This work was supported by the UK Biobank Platform Credits Programme for covering computational costs, the Swiss National Science Foundation (SNSF 310030_200703) and the UZH Candoc Grant (25-024).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Kantonal ethics committee Zurich

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes